Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vanda Pharmaceuticals Narrows FY2025 Sales Guidance from $210.000M-$250.000M to $210.000M-$230.000M vs $224.977M Est

Author: Benzinga Newsdesk | October 29, 2025 03:02pm
Vanda Pharmaceuticals (NASDAQ:VNDA) narrows FY2025 sales outlook from $210.000 million-$250.000 million to $210.000 million-$230.000 million vs $224.977 million estimate.

Posted In: VNDA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist